Blood Biomarker Guides Bladder-sparing Treatment Decisions For Cancer Patients

Circulating tumor DNA, aliases ctDNA, tin foretell metastatic consequence successful patients who person bladder-sparing curen for muscle-invasive bladder cancer, but it is not a bully predictor of section recurrence wrong nan bladder, according to caller information presented coming by Fox Chase Cancer Center researchers.

The study besides showed that nan absence of ctDNA predicted favorable outcomes, sloppy of whether nan patient's bladder was removed aliases not. Circulating tumor DNA are mini fragments of DNA near down by crab cells arsenic they dice disconnected during treatment.

The study, which reports updated information from nan shape 2 RETAIN-2 objective trial, could beryllium utilized to thief guideline curen decisions for patients pinch muscle-invasive bladder crab (MIBC), said first writer Pooja Ghatalia, MD, an Associate Professor successful nan Department of Hematology/Oncology astatine Fox Chase. She conducted nan study pinch elder writer Daniel M. Geynisman, MD, Chief of nan Division of Genitourinary Medical Oncology, and a number of different Fox Chase clinicians.

Test tin thief find treatment

"This tells america ctDNA tin beryllium incorporated into nan decision-making of who should support their bladder and who should not, knowing that we besides request further tests aliases biomarkers to observe section recurrence early successful patients who acquisition progressive surveillance," she said.

In summation to nan findings connected ctDNA, researchers besides reported affirmative results from nan trial, known arsenic RETAIN-2, demonstrating that a response-adapted bladder-preservation attack involving neoadjuvant chemoimmunotherapy tin beryllium considered successful prime patients.

Safely selecting patients for bladder-sparing treatment

Keeping nan bladder intact is simply a precocious privilege for patients undergoing curen for bladder cancer, Ghatalia said. Not only does bladder removal summation nan consequence of complications, but it besides intends patients must deterioration a urine container for nan remainder of their lives, importantly affecting their value of life.

New and amended neoadjuvant therapies mean that much patients whitethorn beryllium capable to beryllium treated for crab without removing nan bladder. However, providers request devices to amended place which patients tin beryllium safely treated pinch this attack and which ones still request to acquisition cystectomy, a room to region nan bladder.

Although ctDNA has antecedently been shown to beryllium an effective instrumentality to foretell outcomes successful patients who person had their bladders removed, this is nan first clip it has been studied successful patients who are treated pinch a bladder preservation approach.

Key findings

• Chemotherapy and immunotherapy were effective for galore patients. More than 70 patients pinch MIBC received operation chemotherapy positive an immunotherapy known arsenic nivolumab. Patients showing complete consequence entered progressive surveillance alternatively of being treated pinch contiguous surgery. Overall, 80% of these patients remained metastasis-free aft 2 years.
• Post-treatment ctDNA predicted metastatic risk. Blood samples were analyzed for ctDNA astatine aggregate timepoints during nan study. Patients who were ctDNA-positive aft curen were overmuch much apt to yet create metastasis.
• Local recurrence was not detected by ctDNA. While nan surveillance group overwhelmingly remained free of metastases, 22 patients subsequently developed a recurrence of crab wrong their bladder. Of these, 19 did not show an summation successful ctDNA, which intends that ctDNA isn't a bully measurement to observe section recurrences.

Looking ahead

Researchers will proceed pursuing patients from nan RETAIN-2 proceedings for 5 years to study semipermanent outcomes of bladder-sparing treatment. They are besides presently designing nan RETAIN-3 objective trial, pinch plans to usage ctDNA arsenic a predictive biomarker successful curen decision-making.

Ghatalia presented results of nan study, "Circulating Tumor DNA (ctDNA) to Guide Response-Adapted Bladder Preservation successful Muscle-Invasive Bladder Cancer (MIBC): Integrated Analysis of nan RETAIN Trials," during a podium position astatine nan 2026 ASCO Genitourinary Cancers Symposium, which is being held February 26-28 successful San Francisco.